Niemann-Pick Type C — Deal Benchmarks & Valuation
Market Analysis
Niemann-Pick Type C is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for niemann-pick type c carry a median total deal value of $2.2B, with upfront payments ranging from $201M to $621M. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones.
Milestone structures for niemann-pick type c deals allocate $398M to development milestones, $452M to regulatory milestones, and $958M to commercial milestones. Royalty rates range from 7.7% to 15.4% at the base tier, with tiered escalation reaching 11.7%-19.4% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for niemann-pick type c licensing?
What royalty rates are standard for niemann-pick type c deals?
How are niemann-pick type c deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.